148 related articles for article (PubMed ID: 21441465)
21. Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo.
Zhang W; Liu S; Liu K; Ji B; Wang Y; Liu Y
Oncol Rep; 2014 Nov; 32(5):1913-22. PubMed ID: 25176394
[TBL] [Abstract][Full Text] [Related]
22. ADAM10 is overexpressed in human hepatocellular carcinoma and contributes to the proliferation, invasion and migration of HepG2 cells.
Yuan S; Lei S; Wu S
Oncol Rep; 2013 Oct; 30(4):1715-22. PubMed ID: 23912592
[TBL] [Abstract][Full Text] [Related]
23. Unfolded protein response signaling by transcription factor XBP-1 regulates ADAM10 and is affected in Alzheimer's disease.
Reinhardt S; Schuck F; Grösgen S; Riemenschneider M; Hartmann T; Postina R; Grimm M; Endres K
FASEB J; 2014 Feb; 28(2):978-97. PubMed ID: 24165480
[TBL] [Abstract][Full Text] [Related]
24. Synergistic effects of co-expression plasmid‑based ADAM10-specific siRNA and GRIM-19 on hepatocellular carcinoma in vitro and in vivo.
Liu S; Zhang W; Liu K; Wang Y; Ji B; Liu Y
Oncol Rep; 2014 Dec; 32(6):2501-10. PubMed ID: 25242535
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
Xargay-Torrent S; López-Guerra M; Montraveta A; Saborit-Villarroya I; Rosich L; Navarro A; Pérez-Galán P; Roué G; Campo E; Colomer D
Clin Cancer Res; 2013 Feb; 19(3):586-97. PubMed ID: 23231952
[TBL] [Abstract][Full Text] [Related]
26. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
27. Fas/FasL-dependent and -independent activation of caspase-8 in doxorubicin-treated human breast cancer MCF-7 cells: ADAM10 down-regulation activates Fas/FasL signaling pathway.
Liu WH; Chang LS
Int J Biochem Cell Biol; 2011 Dec; 43(12):1708-19. PubMed ID: 21854868
[TBL] [Abstract][Full Text] [Related]
28. Retinoids as a perspective in treatment of Alzheimer's disease.
Fahrenholz F; Tippmann F; Endres K
Neurodegener Dis; 2010; 7(1-3):190-2. PubMed ID: 20224284
[TBL] [Abstract][Full Text] [Related]
29. Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation.
Cowan AJ; Frayo SL; Press OW; Palanca-Wessels MC; Pagel JM; Green DJ; Gopal AK
Anticancer Drugs; 2015 Oct; 26(9):974-83. PubMed ID: 26237500
[TBL] [Abstract][Full Text] [Related]
30. The transcription factor PAX2 regulates ADAM10 expression in renal cell carcinoma.
Doberstein K; Pfeilschifter J; Gutwein P
Carcinogenesis; 2011 Nov; 32(11):1713-23. PubMed ID: 21880579
[TBL] [Abstract][Full Text] [Related]
31. Meprin-β regulates production of pro-inflammatory factors via a disintegrin and metalloproteinase-10 (ADAM-10) dependent pathway in macrophages.
Li YJ; Fan YH; Tang J; Li JB; Yu CH
Int Immunopharmacol; 2014 Jan; 18(1):77-84. PubMed ID: 24239627
[TBL] [Abstract][Full Text] [Related]
32. Retinoic acid inhibits the proliferative response induced by CD40 activation and interleukin-4 in mantle cell lymphoma.
Guidoboni M; Zancai P; Cariati R; Rizzo S; Dal Col J; Pavan A; Gloghini A; Spina M; Cuneo A; Pomponi F; Bononi A; Doglioni C; Maestro R; Carbone A; Boiocchi M; Dolcetti R
Cancer Res; 2005 Jan; 65(2):587-95. PubMed ID: 15695403
[TBL] [Abstract][Full Text] [Related]
33. ADAM10 promotes pituitary adenoma cell migration by regulating cleavage of CD44 and L1.
Pan Y; Han C; Wang C; Hu G; Luo C; Gan X; Zhang F; Lu Y; Ding X
J Mol Endocrinol; 2012 Aug; 49(1):21-33. PubMed ID: 22586143
[TBL] [Abstract][Full Text] [Related]
34. Role of ADAM-17, p38 MAPK, cathepsins, and the proteasome pathway in the synthesis and shedding of fractalkine/CX₃ CL1 in rheumatoid arthritis.
Jones BA; Riegsecker S; Rahman A; Beamer M; Aboualaiwi W; Khuder SA; Ahmed S
Arthritis Rheum; 2013 Nov; 65(11):2814-25. PubMed ID: 23897050
[TBL] [Abstract][Full Text] [Related]
35. ADAM10 overexpression in human non-small cell lung cancer correlates with cell migration and invasion through the activation of the Notch1 signaling pathway.
Guo J; He L; Yuan P; Wang P; Lu Y; Tong F; Wang Y; Yin Y; Tian J; Sun J
Oncol Rep; 2012 Nov; 28(5):1709-18. PubMed ID: 22940701
[TBL] [Abstract][Full Text] [Related]
36. Nuclear translocation and signalling of L1-CAM in human carcinoma cells requires ADAM10 and presenilin/gamma-secretase activity.
Riedle S; Kiefel H; Gast D; Bondong S; Wolterink S; Gutwein P; Altevogt P
Biochem J; 2009 May; 420(3):391-402. PubMed ID: 19260824
[TBL] [Abstract][Full Text] [Related]
37. The low affinity IgE receptor (CD23) is cleaved by the metalloproteinase ADAM10.
Lemieux GA; Blumenkron F; Yeung N; Zhou P; Williams J; Grammer AC; Petrovich R; Lipsky PE; Moss ML; Werb Z
J Biol Chem; 2007 May; 282(20):14836-44. PubMed ID: 17389606
[TBL] [Abstract][Full Text] [Related]
38. Fendiline inhibits proliferation and invasion of pancreatic cancer cells by interfering with ADAM10 activation and β-catenin signaling.
Woods N; Trevino J; Coppola D; Chellappan S; Yang S; Padmanabhan J
Oncotarget; 2015 Nov; 6(34):35931-48. PubMed ID: 26440150
[TBL] [Abstract][Full Text] [Related]
39. Triptolide: An inhibitor of a disintegrin and metalloproteinase 10 (ADAM10) in cancer cells.
Soundararajan R; Sayat R; Robertson GS; Marignani PA
Cancer Biol Ther; 2009 Nov; 8(21):2054-62. PubMed ID: 19783906
[TBL] [Abstract][Full Text] [Related]
40. Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells.
Yu J; Tiwari S; Steiner P; Zhang L
Cancer Biol Ther; 2003; 2(6):694-9. PubMed ID: 14688479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
